Context Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CNTX Nasdaq 2830 www.contexttherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Context Therapeutics Inc.

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 - Sep 9th, 2026 5:30 am
Context drops bispecific T-cell engager on cost-cutting initiative - Aug 7th, 2026 5:05 am
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More - Aug 7th, 2026 3:37 am
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - Aug 5th, 2026 2:14 pm
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 10th, 2026 2:05 pm
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - Jul 6th, 2026 2:07 pm
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Jul 5th, 2026 4:08 pm
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Jun 15th, 2026 3:20 pm
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study - Jun 15th, 2026 9:10 am
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - Jun 15th, 2026 4:30 am
Context Therapeutics to Present at the Jefferies Global Healthcare Conference - May 27th, 2026 5:30 am
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - May 18th, 2026 4:45 am
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - May 6th, 2026 2:18 pm
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock - Apr 27th, 2026 8:15 am
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer - Apr 2nd, 2026 5:30 am
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - Mar 23rd, 2026 2:16 pm
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Mar 19th, 2026 5:30 am
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference - Mar 8th, 2026 2:02 pm